Document:

<PAGE>   1
                                                                   EXHIBIT 10.13

                              OFFICER'S CERTIFICATE

         I, the undersigned, do hereby certify and represent that:

         1. I am the duly elected Senior Vice President and Chief Business
Officer of deCODE genetics, Inc., a Delaware Corporation.

         2. Pursuant to Rule 306(a) of Regulation S-T, the following exhibit
10.13 to deCODE genetics, Inc.'s Registration Statement on Form S-1 is a fair
and accurate English translation of a document prepared in the Icelandic
language.

         IN WITNESS WHEREOF, I have signed this Officer's Certificate in my
capacity as Senior Vice President and Chief Business Officer of deCODE genetics,
Inc. on this 7th day of March, 2000.

                       By:     /s/  Hannes T. Smarason
                               -----------------------------------------

                       Name:   Hannes T. Smarason
                       Title:  Senior Vice President and Chief Business Officer

<PAGE>   2

[NOTE: CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN MARKED TO INDICATE THAT
CONFIDENTIALITY HAS BEEN REQUESTED FOR THIS CONFIDENTIAL INFORMATION. THE
CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.]

                             COLLABORATION AGREEMENT
                                     BETWEEN
                  THE ICELANDIC HEART ASSOCIATION, HJARTAVERND
                         AND ISLENSK ERFDAGREINING EHF.

The Icelandic Heart Association, Hjartavernd, (hereinafter "HV") and Islensk
erfdagreining ehf. (hereinafter "IE") hereby enter into the following

                                    Agreement

on collaboration and financing of research into the heredity of certain
disorders.

I.       DECLARATION OF INTENT

HV and IE agree to collaborate on the basis of this Agreement on searching for
genetic factors contributing to the genesis of certain disorders on which HV has
information in its database. Decisions shall be made separately on each
collaboration project, hereinafter referred to as "Research Projects" and a
written protocol and written operating plan will be drawn up for each Research
Project based on this Agreement, cf. Chapters II, IV and V.

The parties to this Agreement undertake to treat all personal information as
confidential, and the parties undertake to observe the guidelines of the Data
Protection Commission (or a specially appointed representative of the Data
Protection Commission) regarding the handling and processing of such information
as well as the conditions of the Science Ethics Committee of the Ministry of
Health.

II.      CONTRIBUTION OF THE PARTIES

HV will supply each Research Project with clinical data and research conclusions
based on the files of participants in previous studies of HV and other clinical
information relating to individual projects.

Specialised staff of HV will be in charge of relations with the individuals
intended for participation in each Research Project, including the performance
of blood sampling. Furthermore, HV will contribute the specialised knowledge of
its heart specialists and genetics experts in the experimental design of each
Research Project, the conduct of experiments and interpretation of their
results.

IE will contribute its expertise in molecular genetics and statistical genetics
in all the areas required to achieve the established objectives of each Research
Project.

IE will also contribute its own equipment and research supplies (reagents) for
use in specially defined projects.

Furthermore, IE will pay to HV all additional costs resulting from the work of
HV on each Research Project (finance the additional material and wage cost
resulting from calling in participants for each individual Research Project and
the necessary sampling).

                                                                             -1-
<PAGE>   3

III.  RIGHTS OF THE PARTIES

IE will own all financial and commercial rights to individual Research Projects
and their conclusions and IE shall have the right to sell them before or after
each Research Project is concluded.

If IE or its parent company, deCODE genetics Inc., succeeds in contracting for
the sale of individual Research Projects or their conclusions or sells the
results of a Research Project to a third party, HV will receive as its share
[CONFIDENTIAL TREATMENT REQUESTED] of all payments to IE or to deCODE genetics
Inc., as applicable, during the term of the contract less the payment of the
research costs and the investment in IE or deCODE genetics Inc.

If IE or deCODE genetics INC. concludes a contract with a third party pursuant
to Paragraph 2 above, IE will pay to HV [CONFIDENTIAL TREATMENT REQUESTED] on
signature of such contract, and thereafter an annual amount of [CONFIDENTIAL
TREATMENT REQUESTED] during the course of the Research Project in question, the
total amount never to exceed [CONFIDENTIAL TREATMENT REQUESTED]. In the event
that the Research Project is concluded in a shorter time than five years by
achieving the objective of the Research Project, HV will receive on such
conclusion the amount which remains unpaid of the [CONFIDENTIAL TREATMENT
REQUESTED] for the Research Project in question. This amount will be paid to HV
for use in its own research other than the research covered by this Agreement,
but not for administrative costs. This payment is in addition to and independent
of the [CONFIDENTIAL TREATMENT REQUESTED] payment pursuant to Paragraph 2 of
this Chapter III.

In the event that it proves necessary to enter into collaboration with other
parties in respect of individual Research Projects, a further agreement shall be
reached on the division of payments between HV and such third party so that the
total payment by IE pursuant to the above remain unchanged.

On signature of this Agreement, IE will pay to HV in confirmation of their
mutual intent to collaborate, [CONFIDENTIAL TREATMENT REQUESTED] which HV shall
own and dispose of without specific commitment on the part of HV. [CONFIDENTIAL
TREATMENT REQUESTED]

IV.      MANAGEMENT

Decisions regarding each Research Project will be taken by HV and IE jointly,
and a Steering Committee will be formed composed of an equal number of
representatives from each party to this Agreement in order to formulate rules on
the arrangement, control and implementation of each Research Project. The
Co-ordinator of each Research Project shall be selected from among the members
of the Steering Committee.

The Steering Committee is also responsible for defining the objectives of each
Research Project and establishing the professional requirements which the
parties to this Agreement approve as appropriate to the conduct of research.

The Steering Committee is responsible for the processing of data and publication
of results pursuant to the rules of Chapter V hereof.

                                                                             -2-
<PAGE>   4

V.       PROCESSING AND DISSEMINATION OF INFORMATION

The results of Research Projects will be published as soon as they fulfil
academic requirements and are fit for publication. In the event that a third
party submits to IE a request for postponement of the publication of results
when they are ready for publication pursuant to the above, the publication may
be delayed for a maximum of 90 days. Efforts shall be made at all times to
safeguard the commercial value of the results by means other than 90 days'
postponement.

The Steering Committee for each Research Project shall decide beforehand on the
Co-ordinator of the Project. As a rule, the Co-ordinator shall be the last
author of scientific articles, but the order of authors shall in other respects
conform to applicable rules in the international scientific community.

VI.      LIMITATIONS ON COLLABORATION WITH OTHER PARTIES

HV covenants not to work with others on individual research projects on heredity
on which a decision has been made to collaborate with IE during the course of
such Research Project. In the event that IE or its parent company, deCODE
genetics INC. have contracted for the sale of the Research Project in question
and the Project leads to a discovery, HV covenants not to enter into
collaboration with other parties on the part of the Research Project which led
to the discovery for five years following the conclusion of the Research Project
or the part of the Project which led to a discovery. However, if the Research
Project does not lead to a discovery, HV is entitled to collaborate with other
parties following the conclusion of the Research Project. However, HV shall
retain its right to take up collaboration with other parties on genetic research
into the risk factors of coronary diseases and arteriosclerosis, but only
provided that individual Research Projects which IE and HV have decided to
collaborate on do not deal with the same subject.

IE covenants that during the course of a Research Project, IE will not take up
collaboration with other parties in the area of the Research Project in question
unless the Steering Committee regards such collaboration as necessary in order
to achieve the objectives of a Research Project. In the event that it should
prove necessary to add new partners to individual Research Projects, the
Steering Committee shall decide on the choice. In the event of a dispute within
the Steering Committee, HV will decide on the choice of additional partners.
However, the provisions of this Paragraph shall not preclude collaboration by IE
in the area of individual Research Projects with the parties who have negotiated
the purchase of the Research Project in question or its conclusions or results,
provided that such collaboration does not prejudice the rights of HV pursuant to
Paragraph 2 of Chapter III.

Subject to the provisions of Paragraph 1 of Chapter III, the parties to this
Agreement agree that this Agreement is not transferable, in part or in its
entirety, to other legal entities or individuals without the consent of both
parties to this Agreement.

VII. TERM AND CONCLUSION OF PROJECT

Collaboration on any individual Research Project shall normally continue for a
term of no longer than five years, or until individual research projects are
concluded. At the conclusion of a Project, all clinical data (DNA and all
information) shall, under all circumstances, be returned to HV. In the event
that one or both parties see reason to

                                                                             -3-
<PAGE>   5

continue their collaboration following the agreed term, such continuation shall
be considered independently.

VII.     SETTLEMENT OF DISPUTES

In the event of a dispute between the parties regarding the implementation of
this Agreement or performance which cannot be resolved within the Steering
Committee, two parties, one from each party to this Agreement, shall attempt to
reach a consensus on settlement of the dispute. In the event that no settlement
can be reached by these two parties within two weeks from the time that the
dispute was submitted to them, each party to this Agreement shall appoint one
arbitrator and the parties to this Agreement jointly request the appointment of
a neutral third arbitrator by the District Court of Reykjavik to participate in
the resolution of the dispute, and the three parties shall constitute an
arbitration tribunal. The tribunal shall conclude their resolution of the
dispute within one month from the time that the tribunal is fully constituted.

The cost of the work of the arbitration tribunal shall be subject to the
decision of the tribunal at each time. The work of the tribunal, procedure and
conclusions before the tribunal shall in other respects be governed, as
applicable, by Act No. 53/1989 on Contractual Arbitration.

Notwithstanding the above provisions on arbitration, issues involving the
collection of payments under this Agreement which are not in dispute between the
parties to this Agreement may be submitted to the courts, as well as any
disputes regarding financial claims which either party may make against the
other party on the basis of the decision of the arbitration tribunal regarding
the default or breach by the other party to this Agreement, provided that the
claim has not previously been submitted to the arbitration tribunal. Such issues
shall be submitted to the District Court of Reykjavik.

This Agreement is done in two identical copies, one to be held by each party to
this Agreement.

Reykjavik 13 February 1998

For Hjartavernd:                               For Islensk erfdagreining ehf.

Magnus Karl Petursson [sign.]                  Kari Stefansson [sign.]

Guomundur Porgeirsson [sign.]

Vilmundur Guonason [sign.]

Nikulas Sigfusson [sign.]

Aslaug Ottesen [sign.]

                                                                             -4-<PAGE>   1
                                                                   EXHIBIT 10.14

                              OFFICER'S CERTIFICATE

         I, the undersigned, do hereby certify and represent that:

         1. I am the duly elected Senior Vice President and Chief Business
Officer of deCODE genetics, Inc., a Delaware Corporation.

         2. Pursuant to Rule 306(a) of Regulation S-T, the following exhibit
10.14 to deCODE genetics, Inc.'s Registration Statement on Form S-1 is a fair
and accurate English translation of a document prepared in the Icelandic
language.

         IN WITNESS WHEREOF, I have signed this Officer's Certificate in my
capacity as Senior Vice President and Chief Business Officer of deCODE genetics,
Inc. on this 7th day of March, 2000.

                       By:     /s/  Hannes T. Smarason
                               --------------------------

                       Name:   Hannes T. Smarason
                       Title:  Senior Vice President and Chief Business Officer

<PAGE>   2

[NOTE: CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN MARKED TO INDICATE THAT
CONFIDENTIALITY HAS BEEN REQUESTED FOR THIS CONFIDENTIAL INFORMATION. THE
CONFIDENTIAL PORTIONS HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION.]

                             COLLABORATION AGREEMENT
                                     BETWEEN
                 DR. HELGI JONSSON AND THORVALDUR INGVARSSON
                         AND ISLENSK ERFDAGREINING EHF.

Dr. Helgi Jonsson and Dr. Thorvaldur Ingvarsson (hereinafter "the Collaborating
Physicians) and Islensk erfdagreining ehf. (hereinafter "IE") hereby enter into
the following

                                    Agreement

on research into osteoarthritis.

I.       SUBJECT OF THE COLLABORATION

The Collaborating Physicians and IE agree to work together pursuant to this
Agreement on searching for genetic factors contributing to the genesis of
osteoarthritis. The proposed collaboration of the parties is hereinafter
referred to as the "Research Project".

II.      CONTRIBUTION OF THE PARTIES

The Collaborating Physicians will supply the Research Project with biological
samples (blood samples), other clinical information and research data which they
possess or have access to regarding patients afflicted with osteoarthritis and
their relatives which are not afflicted with osteoarthritis.

The Collaborating Physicians will be in charge of relations with the individuals
intended for participation in the research, and/or their legal guardians,
including calling them in for blood samples and obtaining the informed consent
of the participants.

Furthermore, the Collaborating Physicians will contribute their specialised
knowledge and expertise regarding diagnosis of disorders, experimental design,
conduct of experiments and interpretation of their results.

IE will contribute its expertise in experimental design, conduct of experiments,
assessment of the heredity of the disorder and interpretation of the results of
research.

IE will also contribute equipment, research supplies, reagents and staff to
conduct experiments. IE will pay the cost of the Research Project, including the
material and wage costs of calling in participants for examination and required
samples. The Collaborating Physicians will submit a financial plan describing in
further detail the projected material and wage costs of the Project, see Annex
A.

III.     RIGHTS OF THE PARTIES

IE will own all financial and commercial rights to the Research Project and its
conclusions. IE will have the right to sell to a third party the conclusions of
the Research Project or its results and to utilise the Research Project
financially in any other manner consistent with recognised ethical standards,
before or after the Research Project is concluded.

                                                                             -1-
<PAGE>   3

IE and its parent company, deCODE genetics Inc., has contracted with a third
party on the sale of the Research Project, its possible conclusions and results.
The amount of the payment of such third party to IE and deCODE genetics Inc.
will depend on the success [CONFIDENTIAL TREATMENT REQUESTED] of all payments by
the third party to IE or to deCODE genetics Inc., as applicable, less the
deduction of the financing by the third party of the research costs and
investment in IE or deCODE genetics Inc.

IE will pay to the Collaborating Physicians jointly [CONFIDENTIAL TREATMENT
REQUESTED] on signature of this Agreement, and thereafter an annual amount of
[CONFIDENTIAL TREATMENT REQUESTED] during the course of the Research Project,
the total amount never to exceed [CONFIDENTIAL TREATMENT REQUESTED]. In the
event that the Research Project is concluded in a shorter time than five years
by achieving the objective of the Research Project, the Collaborating Physicians
will be paid on such conclusion the amount which remains unpaid of the
[CONFIDENTIAL TREATMENT REQUESTED] pursuant to this Paragraph. Payments pursuant
to this Paragraph shall be paid to the Collaborating Physicians for use in their
own research on osteoarthritis. The Collaborating Physicians may establish a
separate research fund for such purpose. Payments pursuant to this Paragraph are
in addition to and independent of the [CONFIDENTIAL TREATMENT REQUESTED] payment
pursuant to Paragraph 2 of this Chapter III. Allocation among the individual
Collaborating Physicians of the research cost payments made by IE to the
Collaborating Physicians pursuant to this Paragraph shall be no concern of IE.
IE is granted full authorisation by the Collaborating Physicians to deliver to
the party accepting the initial payment of IE to the Collaborating Physicians on
behalf of the Collaborating Physicians any payments which may be payable by IE
to the Collaborating Physicians pursuant to the terms of this Agreement.

The right of the Collaborating Physicians to payments pursuant to Paragraphs 2
and 3 of this Chapter III is based on the understanding that IE will not need to
pay other parties for the data and information which the Collaborating
Physicians have undertaken to supply pursuant to Paragraph 1 of Chapter II, and
that it will not be necessary for IE to enter into further collaboration with
other parties in Iceland regarding the study of osteoarthritis in order to
achieve the objectives of the Research Project. In the event that it proves
necessary for IE to negotiate payments to a third party in order to ensure
access to the data and information referred to in Paragraph 1 of Chapter II, or
if it proves necessary for IE to take up collaboration with other parties in
Iceland to achieve the objectives of the research, then the provisions of
Paragraphs 2 and 3 of this Chapter III shall be reviewed so that the total
payments of IE to the Collaborating Physicians and the third party remain the
same as the payments specified in Paragraphs 2 and 3.

IV.      MANAGEMENT

Decisions regarding the Research Project will be taken by the Collaborating
Physicians and IE jointly, and a Steering Committee will be formed composed of
three representatives from each party to this Agreement in order to formulate
rules on the arrangement, control and implementation of the Research Project.
The Co-ordinator of the Research Project shall be selected from among the
members of the Steering Committee.

                                                                             -2-
<PAGE>   4

The Steering Committee is also responsible for defining the objectives of the
Research Project and establishing the professional requirements which the
parties to this Agreement approve as adequate to the conduct of the research.

The Steering Committee is responsible for the processing of data and publication
of results pursuant to the rules of Chapter V hereof.

V.       HANDLING PROCESSING AND DISSEMINATION OF INFORMATION

The parties to this Agreement undertake to treat all personal information as
confidential. The parties to this Agreement undertake to observe the guidelines
of the Data Protection Commission and, as applicable, the specially appointed
representative (observer) of the Data Protection Commission regarding the
handling and processing of such information as well as the guidelines and
conditions of the Science Ethics Committee, which is constituted pursuant to
legislation on Patients' Rights.

The results of the Research Project will be published as soon as they fulfil
academic requirements and are fit for publication. However, IE may postpone such
publication by a maximum of 90 days to provide sufficient time to secure
property rights relating to any invention arising out of the research. In the
event that a third party submits to IE a request for postponement of the
publication of results when they are ready for publication pursuant to the
above, the publication may be delayed for a maximum of 90 days.

The Steering Committee for each Research Project shall decide beforehand on the
Co-ordinator of the Project. As a rule, the Co-ordinator shall be the last
author of scientific articles, but the order of authors shall in other respects
conform to applicable rules in the international scientific community.

VI.      LIMITATIONS ON COLLABORATION WITH OTHER PARTIES

The Collaborating Physicians covenant not to work, jointly or separately, with
others on research into the heredity of osteoarthritis during the course of the
Research Project. The individual Collaborating Physicians covenant not to enter
into collaboration with other parties on the part of the Research Project which
led to a discovery for five years following the conclusion of the Research
Project pursuant to this Agreement. However, if the Research Project does not
lead to a discovery, individual Collaborating Physicians are entitled to take up
collaboration with other parties regarding research into the heredity of
osteoarthritis following the conclusion of the Research Project.

IE covenants that during the course of the Research Project, IE will not take up
collaboration with other parties on research into the heredity of osteoarthritis
unless the Steering Committee regards such collaboration as necessary in order
to achieve the objectives of the Research Project. In the event that it should
prove necessary to add new partners to the Research Project, the Steering
Committee shall decide on the choice of such partner. In the event of a dispute
within the Steering Committee, the Collaborating Physicians will decide on the
choice of additional partners. Notwithstanding the above, the provisions of this
Paragraph shall not preclude collaboration by IE in the area of the Research
Project with the parties who have negotiated the purchase of the Research
Project, its conclusions or results, provided

                                                                             -3-
<PAGE>   5

that such collaboration does not prejudice the rights of the collaboration group
pursuant to Paragraphs 2 and 3 of Chapter III.

VII. TERM AND CONCLUSION OF PROJECT

The Research Project shall continue for a term of five years following the
signature of this Agreement unless it is concluded earlier. In the event of
substantial default by either party to this Agreement the other party may
terminate this Agreement. In the event of a dispute regarding the termination
rights of a party, such dispute shall be resolved pursuant to the terms of
Chapter VIII.

At the conclusion of the Project, all clinical data (blood samples and clinical
information) shall be returned to the Collaborating Physicians.

In the event that one or both parties see reason to continue their collaboration
following the agreed term, such continuation shall be considered independently.

VIII.    SETTLEMENT OF DISPUTES

In the event of a dispute between the parties regarding the implementation of
this Agreement or performance which cannot be resolved within the Steering
Committee, two parties, one from each party to this Agreement, shall attempt to
reach a consensus on settlement of the dispute. In the event that no consensus
can be reached by these two parties within two weeks from the time that the
dispute was submitted to them, each party to this Agreement shall appoint one
arbitrator and the parties to this Agreement shall then jointly request the
appointment of a neutral third arbitrator by the District Court of Reykjavik to
participate in the resolution of the dispute, and the three parties shall
constitute an arbitration tribunal. The tribunal shall conclude their resolution
of the dispute within one month from the time that the tribunal is fully
constituted.

The cost of the work of the arbitration tribunal shall be subject to the
decision of the tribunal at each time. The work of the tribunal, procedure and
conclusions before the tribunal shall in other respects be governed, as
applicable, by Act No. 53/1989 on Contractual Arbitration.

Notwithstanding the above provisions on arbitration, issues involving the
collection of payments under this Agreement which are not in dispute between the
parties to this Agreement may be submitted to the courts, as well as any
disputes regarding financial claims which either party may make against the
other party on the basis of the decision of the arbitration tribunal regarding
the default or breach by the other party to this Agreement, provided that the
claim has not previously been submitted to the arbitration tribunal. Such issues
shall be submitted to the District Court of Reykjavik.

Reykjavik 31 March 1998

For the Collaborating Physicians:       For Islensk erfdagreining ehf.

Dr. Helgi Jonsson [sign.]               Kari Stefansson, Managing Director
                                        [sign.]

Dr. Thorvaldur Ingvarsson [sign.]

                                                                             -4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]